MTOR and cancer: The coadministration of TPA and EGCG in cancer model systems might be a promising approach to promote both the synergic inhibition of AR signalling mediated by the LMTK2 inhibitory action and the down regulation of PI3K-Akt-mTOR pathway directly by means of EGCG.